Literature DB >> 33823214

Risk stratification in patients with residual pulmonary hypertension after pulmonary endarterectomy.

Stefano Ghio1, Catherine Klersy2, Angelo Corsico3, Sofia Lucia Gamba4, Cristian Monterosso4, Joice Masiglat5, Ermelinda Borrelli5, Laura Scelsi6, Alessandra Greco6, Davide Piloni3, Luigi Oltrona Visconti6, Andrea Maria D'Armini7.   

Abstract

BACKGROUND: Few studies addressed the issue of risk stratification in patients with residual pulmonary hypertension (PH) after pulmonary endarterectomy (PEA). This study tested the potential added value of parameters that have not been included in existing risk models.
METHODS: We evaluated 546 consecutive patients with chronic thromboembolic pulmonary hypertension who underwent PEA and were followed-up for a median period of 58 months.
RESULTS: Among the 242 with residual PH, 27 died and had 127 a clinical worsening event. At univariable analysis, the parameters associated with poor survival were pulmonary vascular resistance (PVR) ≥425 dyn·s·cm-5 (p ≤ 0.001), mean pulmonary artery pressure (mPAP) ≥38 mmHg (p = 0.003) and pulmonary artery compliance (CPA) ≤1.8 ml/mmHg (p = 0.014). In the bivariable models including either PVR or mPAP as first parameter, the addition of CPA was not statistically significant. The parameters associated with poor clinical worsening were CPA ≤1.8 ml/mmHg (p < 0.001), PVR ≥425 dyn·s·cm-5 (p = 0.002), arterial oxygen tension (PaO2) ≤ 75 mmHg (p = 0.003), mPAP ≥38 mmHg (p = 0.008). In a multivariable analysis which included PVR ≥425 as the first parameter, the addition of both CPA ≤1.8 ml/mmHg and of PaO2 ≤ 75 mmHg significantly improved prognostic stratification (Harrel's C of the model = 0.64, p < 0.001). Noticeably, the lower tertile of the model's predictor index identified a subgroup of 91 patients who had an event rate numerically similar to that of patients without residual PH.
CONCLUSIONS: Risk stratification in residual PH can be refined if CPA and PaO2 are considered in association with standard hemodynamic parameters.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Endarterectomy; Prognosis; Pulmonary hypertension

Mesh:

Year:  2021        PMID: 33823214     DOI: 10.1016/j.ijcard.2021.04.003

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension: a systematic review.

Authors:  John D L Brookes; Crystal Li; Sally T W Chung; Elizabeth M Brookes; Michael L Williams; Nicholas McNamara; Sofia Martin-Suarez; Antonio Loforte
Journal:  Ann Cardiothorac Surg       Date:  2022-03

2.  Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic.

Authors:  Pavel Jansa; David Ambrož; Matyáš Kuhn; Vladimír Dytrych; Michael Aschermann; Vladimír Černý; Virginie Gressin; Samuel Heller; Jan Kunstýř; Michal Širanec; Ci Song; Aleš Linhart; Jaroslav Lindner; Audrey Muller
Journal:  Pulm Circ       Date:  2022-03-28       Impact factor: 2.886

Review 3.  Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis.

Authors:  Pengwei Wang; Jiaxin Deng; Quanying Zhang; Hongyan Feng; Yongheng Zhang; Yizhong Lu; Lizhu Han; Pengfei Yang; Zhijian Deng
Journal:  Front Pharmacol       Date:  2022-02-09       Impact factor: 5.810

4.  Is Pulmonary Artery Pulsatility Index (PAPi) a Predictor of Outcome after Pulmonary Endarterectomy?

Authors:  Sofia Martin-Suarez; Gregorio Gliozzi; Giulio Giovanni Cavalli; Valentina Orioli; Antonio Loforte; Saverio Pastore; Barbara Rossi; Davide Zardin; Nazzareno Galiè; Massimiliano Palazzini; Fabio Dardi; Francesco Saia; Fabio Niro; Davide Pacini
Journal:  J Clin Med       Date:  2022-07-27       Impact factor: 4.964

5.  Different response of the oxygen pathway in patients with chronic thromboembolic pulmonary hypertension treated with pulmonary endarterectomy versus balloon pulmonary angioplasty.

Authors:  Zhihui Fu; Xincao Tao; Wanmu Xie; Peiran Yang; Qian Gao; Jinzhi Wang; Zhenguo Zhai
Journal:  Front Cardiovasc Med       Date:  2022-09-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.